Bradley McGregor, MD, explains how despite major advances in metastatic renal cell carcinoma, there are still patients who do not respond or maintain their initial response to the novel treatment option. Therefore, McGregor, says there remains a need for novel treatment targets and therapies in this space. McGregor is clinical director, Lank Center for Genitourinary Oncology, senior physician, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute.
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology
January 19th 2023“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
2 Clarke Drive
Cranbury, NJ 08512